Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7397 p470
22 April 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Some COPD exacerbations need antibiotic treatment

John Cole/Science Photo Library

Antibotic treatment

Patients admitted to hospital benefit most from antibotic treatment

Exacerbations of chronic obstructive pulmonary disease associated with increased cough and sputum purulence should be treated with antibiotics, according to a review published online in The Cochrane Database of Systematic Reviews (19 April 2006).

There is conflicting evidence as to whether acute COPD exacerbations should be treated with antibiotics, say the reviewers. They conducted a systematic review of 11 trials with 917 patients to estimate the value of antibiotics in the management of acute COPD exacerbations.

The reviewers found that, regardless of choice, antibiotics reduced the risk of death by 77 per cent (relative risk 0.23, 95 per cent confidence interval 0.10–0.52); decreased the risk of treatment failure by 53 per cent (RR 0.47, 95 per cent CI 0.36–0.62); and reduced the risk of sputum remaining purulent by 44 per cent (RR 0.56, 95 per cent CI 0.41–0.77). However, antibiotics also increased the risk of diarrhoea (RR 2.86, 95 per cent CI 1.06–7.76).

“This effect is greatest in the severe group of patients who are admitted to hospital. Analysis restricted to community-based studies did not find differences between antibiotic and placebo,” say the reviewers

The results should be interpreted with caution owing to differences in patient selection, choice of antibiotic and the small number of trials included, they add. “Nevertheless, this review supports the use of antibiotics for most patients with increased cough and sputum purulence with exacerbations of COPD who are moderately or severely ill.”

Back to Top


©The Pharmaceutical Journal